NHS England | pharmaphorum

Skip to main content

Wednesday 22 July 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

NHS England

Views & Analysis

NHS

Pharma could take NHS England to court over new delaying tac...

New cost-capping and delaying measures will further restrict access to new medicines say pharma and patient groups.

News

NICE1

Pharma attacks plan to ration new drugs in England

Plans to ration and delay use of novel drugs in England have been condemned by the pharma industry and a health charity.

News

heart-840x470

Digital heart scan can save NHS millions

HeartFlow could save NHS England a minimum of around £9.1 million by 2022.

News

Strensiq

Alexion lambasts NICE over rare disease ruling

Watchdog accused of ignoring stakeholder consensus and call for negotiations

Views & Analysis

2017 year

UK Pharmaceutical Leaders Survey 2017: Brace for Turbulence

A look ahead to the UK market in 2017 through the eyes of pharma industry leaders

Views & Analysis

Fast track 600

Fast-track appraisals and Managed Access Agreements

Experts discuss England’s proposed ‘fast-track’ appraisals for new treatments, plus MAAs.

Load more results

Editor's Picks

Novo's Wegovy pill cleared for weight loss in EU

Lilly buys into psychedelics with $3.8bn AtaiBeckley deal

Bayer's Kerendia on course for NHS use in heart failure

MSD gets first FDA okay for oral PCSK9 cholesterol drug

GSK abandons cough drug added in $2bn Bellus deal

News

Repligen builds in cell therapy with $1.5bn BioLife takeover

Repligen builds in cell therapy with $1.5bn BioLife takeover

Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company